All In Biotech

Drug Trial Radar · NCT04377555

Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

An Open-Label, Prospective, Single-arm, Multi-center Study to Assess Disease Activity and Biomarkers of Neuronal Damage in Minority Patients With Relapsing Multiple Sclerosis Receiving Treatment With Ocrelizumab

Last checked: Nov 20, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

179

Actual

Start

Jul 30, 2020

Primary completion

Dec 15, 2022

Study completion Nov 11, 2025

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
May 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open-label, prospective, single-arm, multi-center study to assess disease activity and biomarker of neuronal damage in minority patients (self-identified Black or African American (AA) and Hispanic/Latino (HA) patients with relapsing multiple sclerosis (RMS) receiving treatment with Ocrelizumab. The study plans to enroll approximately 150 participants (75 AA and 75 HA) with 50 participants enrolled in a CSF sub-study.

Conditions

  • Multiple Sclerosis, Relapsing

Interventions

  • OcrelizumabDrug

    Ocrelizumab will be administered intravenously (IV) at a dose of 600 mg every 24 weeks. The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent dose, ocrelizumab will be administered as a single 600 mg IV infusion every 24 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants Free of Any Protocol-defined Events During a 48-week Period on TreatmentTime frame: 48 Weeks

Locations

28 sites in 3 countries. Site status is shown where the registry gives one.

  • Barrow Neurological Institute

    Phoenix, Arizona

  • Keck School of Medicine of USC

    Los Angeles, California

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Baptist Neurology - Beaches

    Jacksonville Beach, Florida

  • University of Miami Miller School of Medicine

    Miami, Florida

  • Shepherd Center Inc.

    Atlanta, Georgia

  • Atlanta Neuroscience Institute

    Atlanta, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • Josephson Wallack Munshower Neurology PC

    Indianapolis, Indiana

  • University of Maryland Medical Center

    Baltimore, Maryland

  • Johns Hopkins University Neurology Research Office

    Baltimore, Maryland

  • Wayne State University

    Detroit, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • Hackensack University Medical Center

    Paramus, New Jersey

  • SUNY Upstate Medical Center

    Syracuse, New York

  • Guilford Neurologic Research Partners, LLC

    Greensboro, North Carolina

  • Jefferson University Hospitals, Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Neurology Clinic - Cordova

    Cordova, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • North Texas Institute of Neurology and Headache NextStage Clinical Research Clinic

    Frisco, Texas

  • Baylor College of Medicine Medical Center

    Houston, Texas

  • Multiple Sclerosis Center of Tidewater

    Norfolk, Virginia

  • Wheaton Franciscan Healthcare - St. Francis Outpatient Center

    Milwaukee, Wisconsin

  • Froedtert and The Medical College of Wisconsin

    Milwaukee, Wisconsin

  • The Aga Khan University-Kenya.

    Nairobi, Kenya

  • Centro Internacional De Mercadeo

    Guaynabo, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.